Clinical Scorecard: Efficacy and Safety of DLL3-Targeted CAR-T Therapy Enhanced with dnTGFBR2 in a Patient with Recurrent Small-Cell Lung Cancer: A Case Study
At a Glance
Category
Detail
Condition
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Key Mechanisms
DLL3-targeted CAR-T therapy with dominant-negative TGFBR2 armor to overcome immunosuppressive tumor microenvironment.
Target Population
Patients with recurrent or refractory ES-SCLC.
Care Setting
Investigational therapy in a real-world setting.
Key Highlights
Patient demonstrated a durable partial response with a 35% reduction in target lesions at 12 weeks post-infusion.
No dose-limiting toxicity, cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity (ICANS) observed.
Patient maintained an ECOG performance status of 1 and experienced resolution of cancer-related pain after 1 year.
Guideline-Based Recommendations
Diagnosis
Diagnosis of ES-SCLC confirmed through imaging and biopsy.
Management
Consider investigational therapies like LB2102 for patients ineligible for clinical trials.
Monitoring & Follow-up
Monitor for cytopenias and inflammatory markers post-infusion.
Risks
Potential for CNS involvement and complications from prior treatments.
Patient & Prescribing Data
51-year-old female with recurrent ES-SCLC.
Single infusion of LB2102 led to significant tumor response and manageable side effects.
Clinical Best Practices
Educate patients and families about treatment protocols and compliance.
Monitor for adverse effects and manage symptoms proactively.
by Chelsey M. Williams, Susanne M. Arnold, John L. Villano, Erika N. Amarilla Alonso, Christine F. Brainson, Paul O. Schwarzenberger, Sahista Vahora, Ayman Qasrawi, Reinhold Munker, B. Mark Evers, Zhonglin Hao
Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.
